10 papers in the library · 71 citations · publishing 2018-2026
The British Journal of Psychiatry February 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al.
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Journal of Psychiatric Research November 27, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Joanna Róg et al. 3 citations
BACKGROUND: Major depressive disorder (MDD) is a leading cause of global disability, and current treatments often fail to provide sustained effectiveness. MDMA-assisted therapy (MDMA-AT) is a promising treatment for MDD. However, the long-term effects are not known. OBJECTIVES: To examine the long-term effects of MDMA-AT for MDD. METHODS: Twelve participants with MDD and an ongoing moderate to...
Frontiers in Psychiatry September 26, 2025 Cato Grønnerød, Thea Rønningen, Ingrid Rike Haugsjå et al.
The purpose of the article: In recent years, a renewed interest has emerged in investigating the use of MDMA in the treatment of mental disorders. However, knowledge about the characteristics of recreational use of MDMA, its contexts and effects are limited. Methods: We recruited adult Norwegian participants aged 18 to 65 who reported having had a memorable experience after using MDMA. They...
The British Journal of Psychiatry July 11, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al. 6 citations
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic stress disorder, but has not been investigated for a primary diagnosis of major depressive disorder (MDD). We aimed to explore the proof of principle and safety as a first study with MDMA-AT for MDD, and to provide preliminary efficacy data. Twelve...
Journal of Psychiatric Research May 26, 2025 Bjørn Holmøy, Tor-Morten Kvam, Kristoffer Andreas Aamodt Andersen et al. 3 citations
Psychedelic drugs, known for their potent psychoactive effects, have gained attention for their potential therapeutic benefits in treating mental disorders. However, distressing experiences induced by psychedelics can lead to adverse long-term effects. To better assess these experiences, we aimed to provide a Norwegian translation and psychometric validation of the Challenging Experience...
Frontiers in Pharmacology 2025 Paula Aarseth Tunstad, Tor-Morten Kvam, Malin V. Uthaug et al. 2 citations
Interest in the therapeutic effects of classical psychedelics has risen recently. However, little epidemiological knowledge exists about the use of classical psychedelics in Scandinavian countries. Additionally, there is a limited understanding of what factors drive self-reported improvement in wellbeing. The aim of this study was to investigate the relationship between the use of classical...
Frontiers in Psychiatry November 13, 2023 Tor-Morten Kvam, Malin V. Uthaug, Kristoffer A A Andersen et al. 21 citations
Objective In recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid diethylamide (LSD) in the treatment of mental disorders and substance use disorders. However, knowledge about the epidemiology of classic psychedelics in the Nordic countries is limited. Methods We recruited adult, Norwegian participants who have had...
Frontiers in Psychiatry October 26, 2022 Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al. 11 citations
Background Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and there is a significant need for more effective treatment options. Here we present the protocol for an investigator-initiated and publicly funded trial of MDMA-assisted therapy (MDMA-AT) for MDD. This single-site, open-label study investigates the...
Journal of Psychedelic Studies April 16, 2021 Henrik Børsting Jacobsen, Audun Stubhaug, Bjørn Holmøy et al. 10 citations
Abstract Background Psilocybin is emerging as a promising therapeutic agent for a wide range of psychiatric conditions, and clinical trials on psilocybin-assisted treatment are forthcoming in Scandinavian countries. However, little is known about attitudes towards this psychedelic compound among the general public in Nordic countries. This might represent a confound, and reduce the validity of...
Tidsskrift for Den norske legeforening 2018 Tor-Morten Kvam, Lowan H. Stewart, Ole A. Andreassen 15 citations
Psykedeliske stoffer i behandling av flere psykiske lidelser har vist lovende resultater, men studiene er små og har metodologiske utfordringer. Det er behov for systematiske kliniske studier for å skaffe solid dokumentasjon for effekt og etablere rutiner for overvåkning av mulige bivirkninger.